Intro

This chapter explores the LORA trial, which investigates osimertinib treatment after chemoradiation in patients with unresectable stage III EGFR-mutated NSCLC. It also provides insights on NSCLC staging, explaining the criteria and key characteristics for stages one through three.

Transcript

Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!

Get the app